MAP2K7 and melanoma: BRAF V600E mutations are essential to guide treatment decision-making: indeed, melanomas harboring BRAF V600 mutations are generally responsive to BRAF inhibitors (BRAFi) and/or MEK inhibitors (MEKi), which, therefore, are the main targeted agents for melanoma therapy [57].